BGIM
NEOS

Brandywine Global Investment Management’s Neos Therapeutics, Inc NEOS Stock Holding History

Brandywine Global Investment Management’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-122,404
Closed -$76K – 722
2020
Q4 		$76K Buy
122,404
+1,801
+1% +$1.11K ﹤0.01% 619
2020
Q3 		$64K Sell
120,603
-4,700
-4% -$3.19K ﹤0.01% 585
2020
Q2 		$86K Buy
125,303
+1,900
+2% +$1.51K ﹤0.01% 632
2020
Q1 		$93K Buy
123,403
+708
+0.6% +$973 ﹤0.01% 644
2019
Q4 		$178K Buy
122,695
+27,495
+29% +$41.2K ﹤0.01% 656
2019
Q3 		$141K Hold
95,200
– – ﹤0.01% 660
2019
Q2 		$123K Buy
95,200
+31,029
+48% +$57.1K ﹤0.01% 669
2019
Q1 		$168K Sell
64,171
-9,445
-13% -$22.1K ﹤0.01% 647
2018
Q4 		$122K Sell
73,616
-11,220
-13% -$31.5K ﹤0.01% 664
2018
Q3 		$412K Buy
84,836
+172
+0.2% +$975 ﹤0.01% 597
2018
Q2 		$530K Sell
84,664
-2,020
-2% -$15.1K ﹤0.01% 611
2018
Q1 		$720K Buy
86,684
+69,157
+395% +$660K ﹤0.01% 596
2017
Q4 		$179K Buy
+17,527
New +$168K ﹤0.01% 707

Brandywine Global Investment Management's NEOS Position: Q1 2021 in Review

Brandywine Global Investment Management sold out of Neos Therapeutics, Inc (NEOS) in Q1 2021, closing a stake of 122,404 shares — an estimated $76K sold.

Brandywine Global Investment Management first reported a position in NEOS in Q4 2017 and held it in 13 quarters. The position peaked at $720K in Q1 2018. 0 funds tracked by Wall St. Rank hold NEOS as of Q1 2021.

  • Brandywine Global Investment Management reported no remaining Neos Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
  • Brandywine Global Investment Management sold 122,404 Neos Therapeutics, Inc shares in Q1 2021, an estimated $76K.
  • Brandywine Global Investment Management first reported a position in Neos Therapeutics, Inc in Q4 2017 and held it in 13 quarters.
  • Brandywine Global Investment Management's Neos Therapeutics, Inc position peaked at $720K in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2021.

Based on Brandywine Global Investment Management's 13F filing for Q1 2021, filed 13 May 2021.